Western medicine development
Western Medicine Development - Chipscreen Biosciences A Pioneer in Drug Innovation & Development in China
Founded in March 2001 by a group of senior scientists returned from the United States, Chipscreen Biosciences focuses on developing innovative drugs with new mechanisms of action (MOA) for the treatment of human diseases in four major therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, and neurodegenerative diseases, so as to provide patients with affordable, clinically urgent, and revolutionary drugs to meet their unmet clinical needs. Chipscreen Biosciences was the first biotech firm approved for listing on the Shanghai Stock Exchange STAR Market (Stock code: 688321.SH).
Leveraging its independently developed, internationally advanced integrated platform that combines AI-assisted drug design with chemical genomics, Chipscreen Biosciences has built a robust pipeline of innovative therapeutics across various stages of research and development. Currently, the company has two innovative drugs (Chidamide for oncology, Chiglitazar sodium for type 2 diabetes) with multiple indications marketed globally,
Chipscreen Biosciences has established a global footprint with operations in Shenzhen, Chengdu, Pengzhou, Beijing, Shanghai, and the U.S. subsidiary ThalassaX Therapeutics United States Ltd. It has filed more than 800 invention patents in China and abroad, with more than 250 granted.